The Latest Breaking News from RBC Capital

RBC Capital says Edgewise Therapeutics Inc's (NASDAQ:EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October…

Upgrades

RBC Capital cut Verizon Communications Inc. (NYSE: VZ) price target from $57 to $54. Verizon shares fell 0.9% to $50.22 in pre-market trading.

RBC Capital has decided to maintain its Outperform rating of Olin (NYSE:OLN) and lower its price target from $83.00 to $76.00. Shares of Olin are trading down 9.08% over the last 24 hours, at $52.02 per share. A move to $76.00 would account for a 46.11% increase from the current…

RBC Capital analyst Daniel. R. Perlin looked forward to the Fintech Conference on June 14. Investor feedback was generally constructive, with most investors focused on which names in its universe have the higher probability for positive revisions in 2H/22 versus names at risk. 

RBC Capital has decided to maintain its Outperform rating of DocuSign (NASDAQ:DOCU) and lower its price target from $85.00 to $80.00. Shares of DocuSign are trading down 24.11% over the last 24 hours, at $66.30 per share. A move to $80.00 would account for a 20.66% increase from the current…

RBC Capital has decided to maintain its Sector Perform rating of Casey's General Stores (NASDAQ:CASY) and lower its price target from $250.00 to $238.00. Shares of Casey's General Stores are trading down 4.01% over the last 24 hours, at $197.97 per share.

With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ:VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens.  With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a…

Analysts acknowledged GitLab Inc's (NASDAQ:GTLB) Q1 beat by re-rating the stock. RBC Capital analyst Matthew Hedberg maintained GitLab with an Outperform and raised the price target from $64 to $66. GitLab reported a solid start to the year as execution continued in its third quarter as a public company, Hedberg noted.  Revenue growth again accelerated while RPO…

RBC Capital analyst Jonathan Atkin maintained Cyxtera Technologies Inc (NASDAQ:CYXT) with an Outperform and raised the price target from $14 to $16. Atkin's recent fireside chat and meetings with CFO Carlos Sagasta at RBC's Global Communications Infrastructure conference touched on multiple financial, strategic, and operating topics.  Atkins updated his model and increased the price target…

RBC Capital analyst Joseph Spak